Literature DB >> 18178609

Leptin and the risk of Barrett's oesophagus.

B J Kendall1, G A Macdonald, N K Hayward, J B Prins, I Brown, N Walker, N Pandeya, A C Green, P M Webb, D C Whiteman.   

Abstract

BACKGROUND: Obesity is associated with increased risks of Barrett's oesophagus and oesophageal adenocarcinoma. Alterations in serum leptin and adiponectin, obesity-related cytokines, have been linked with several cancers and have been postulated as potential mediators of obesity-related carcinogenesis; however, the relationship with Barrett's oesophagus remains unexplored.
METHODS: Serum leptin and adiponectin concentrations were measured on two subsets of participants within a case-control study conducted in Brisbane, Australia. Cases were people aged 18-79 years with histologically confirmed Barrett's oesophagus newly diagnosed between 2003 and 2006. Population controls, frequency matched by age and sex to cases, were randomly selected from the electoral roll. Phenotype and medical history data were collected through structured, self-completed questionnaires. Odds ratios (OR) and 95% CI were calculated using multivariable logistic regression analysis.
RESULTS: In the pilot analysis (51 cases, 67 controls) risks of Barrett's oesophagus were highest among those in the highest quartile of serum leptin (OR 4.6, 95% CI 0.6 to 33.4). No association was seen with adiponectin. In the leptin validation study (306 cases, 309 controls), there was a significant threefold increased risk of Barrett's oesophagus among men in the highest quartile of serum leptin (OR 3.3, 95% CI 1.7 to 6.6) and this persisted after further adjustment for symptoms of gastro-oesophageal reflux (OR 2.4, 95% CI 1.1 to 5.2). In contrast, the risk of Barrett's oesophagus among women decreased with increasing serum leptin concentrations.
CONCLUSIONS: High serum leptin is associated with an increased risk of Barrett's oesophagus among men but not women. This association is not explained simply by higher body mass or gastro-oesophageal reflux among cases. The mechanism remains to be determined.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18178609     DOI: 10.1136/gut.2007.131243

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  59 in total

Review 1.  The role of obesity in oesophageal cancer development.

Authors:  Elizabeth Long; Ian L P Beales
Journal:  Therap Adv Gastroenterol       Date:  2014-11       Impact factor: 4.409

2.  Repositioning leptin as a therapy for Alzheimer's disease.

Authors:  Jane M Johnston; Steven J Greco; Ashkan Hamzelou; J Wesson Ashford; Nikolaos Tezapsidis
Journal:  Therapy       Date:  2011-09

Review 3.  Risk factors for neoplastic progression in Barrett's esophagus.

Authors:  Elizabeth F Wiseman; Yeng S Ang
Journal:  World J Gastroenterol       Date:  2011-08-28       Impact factor: 5.742

4.  Serum leptin and adiponectin levels and risk of Barrett's esophagus and intestinal metaplasia of the gastroesophageal junction.

Authors:  Olivia M Thompson; Shirley A A Beresford; Elizabeth A Kirk; Mary P Bronner; Thomas L Vaughan
Journal:  Obesity (Silver Spring)       Date:  2010-01-28       Impact factor: 5.002

Review 5.  Barrett esophagus: an update.

Authors:  Rami J Badreddine; Kenneth K Wang
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-06-01       Impact factor: 46.802

6.  Associations of diabetes mellitus, insulin, leptin, and ghrelin with gastroesophageal reflux and Barrett's esophagus.

Authors:  Joel H Rubenstein; Hal Morgenstern; Daniel McConell; James M Scheiman; Philip Schoenfeld; Henry Appelman; Laurence F McMahon; John Y Kao; Val Metko; Min Zhang; John M Inadomi
Journal:  Gastroenterology       Date:  2013-08-30       Impact factor: 22.682

Review 7.  Central adiposity is associated with increased risk of esophageal inflammation, metaplasia, and adenocarcinoma: a systematic review and meta-analysis.

Authors:  Siddharth Singh; Anamay N Sharma; Mohammad Hassan Murad; Navtej S Buttar; Hashem B El-Serag; David A Katzka; Prasad G Iyer
Journal:  Clin Gastroenterol Hepatol       Date:  2013-05-22       Impact factor: 11.382

8.  Circulating inflammatory cytokines and adipokines are associated with increased risk of Barrett's esophagus: a case-control study.

Authors:  Jose M Garcia; Andres E Splenser; Jennifer Kramer; Abeer Alsarraj; Stephanie Fitzgerald; David Ramsey; Hashem B El-Serag
Journal:  Clin Gastroenterol Hepatol       Date:  2013-08-15       Impact factor: 11.382

Review 9.  Gastrointestinal Complications of Obesity.

Authors:  Michael Camilleri; Harmeet Malhi; Andres Acosta
Journal:  Gastroenterology       Date:  2017-02-10       Impact factor: 22.682

10.  The risk of Barrett's esophagus associated with abdominal obesity in males and females.

Authors:  Bradley J Kendall; Graeme A Macdonald; Nicholas K Hayward; Johannes B Prins; Suzanne O'Brien; David C Whiteman
Journal:  Int J Cancer       Date:  2012-10-30       Impact factor: 7.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.